Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases

被引：1
|
作者：
Lai-Tiong, F. [1 ]
机构：
[1] Gard Canc Inst, Oncol Unit, Rue Prof Henri Pujol, F-30900 Nimes, France
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2018年 / 39卷 / 05期
关键词：
Pertuzumab; Her2-positive breast cancer; Metastases; Complete response;
D O I：
10.12892/ejgo4026.2018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Her2-positive breast cancers represent about 20 percent of breast cancer patients. Her2-positive breast cancers have more aggressive and poorer prognosis. However, with the emergence of new therapies, outcomes have changed with improvement in survival. Pertuzumab is a new drug, a monoclonal antibody against Her2, available for use in the treatment of Her2-positive breast cancer.
引用
收藏
页码：845 / 846
页数：2
相关论文
共 50 条
  • [41] When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?
    Beda, Manuela
    Basso, Umberto
    Ghiotto, Cristina
    Monfardini, Silvio
    TUMORI JOURNAL, 2007, 93 (05): : 491 - 492
  • [42] Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, J.
    Sethunath, V.
    Qin, L.
    Shea, M. J.
    Mitchell, T.
    De Angelis, C.
    Nanda, S.
    Diala, I.
    Lalani, A. S.
    Hilsenbeck, S. G.
    Rimawi, M. F.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Shea, Martin J.
    Mitchell, Tamika
    Pereira, Resel
    Qin, Lanfang
    Nanda, Sarmistha
    De Angelis, Carmine
    Goutsouliak, Kristina
    Diala, Irmina
    Lalani, Alshad S.
    Mehravaran, Sepideh
    Hilsenbeck, Susan G.
    Nagi, Chandandeep
    Gutierrez, Carolina
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2019, 79 (13)
  • [44] Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
    Tas, Faruk
    Ozturker, Can
    BREAST JOURNAL, 2020, 26 (05): : 1004 - 1006
  • [45] Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Madden, Rebecca
    Kosari, Sam
    Peterson, Gregory M.
    Bagheri, Nasser
    Thomas, Jackson
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (02) : 72 - 80
  • [46] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [47] Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment
    Cortes, J.
    Gelmon, K.
    Fumoleau, P.
    Wardley, A.
    Verma, S.
    Contes, P. F.
    Gianni, L.
    Kirk, S. J.
    McNally, V.
    Baselga, J.
    EJC SUPPLEMENTS, 2008, 6 (07): : 217 - 217
  • [48] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [49] Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    Huang, Shang-Xiao
    Wang, Han-Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 252 - +
  • [50] A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab plus Trastuzumab plus Docetaxel vs. Placebo plus Trastuzumab plus Docetaxel in Patients with Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA)
    Baselga, J.
    Kim, S-B
    Im, S-A
    Hegg, R.
    im, Y-H
    Roman, L.
    Pedrini, J. L.
    Cortes, J.
    Knott, A.
    Clark, E.
    Ross, G. A.
    Swain, S. M.
    CANCER RESEARCH, 2011, 71
12345